All News
Bimekizumab Safety in Psoriasis Patients
A pooled analyses of data from eight, phase 2 and 3 randomized clinical trials shows bimekizumab, a dual IL-17A/F inhibitor, to be effective in plaque psoriasis and was well tolerated aside from an increased incidence of mild to moderate oral candidiasis.
Read ArticleCOVID-19 Death is Dependent on Age and Type I IFN Autoantibodies
A study in PNAS of has shown that autoantibodies against type I interferons (IFNs) are strong predictors of death from COVID-19.
Read ArticleDoes Sunlight Trigger Lupus?
Whether exposure to ultraviolet (UV) radiation from the sun can cause new-onset systemic lupus erythematosus (SLE) wasn't settled by data from a large, long-running epidemiologic study, but the trends indicated that it could.
Read ArticleModest Benefits of Diet on Arthritis
A EULAR taskforce systematically reviewd the literature on the effects of diet and lifestyle behaviors in rheumatic and musculoskeletal diseases (RMDs), and found little evidence suggesting dietary factors can substantially affect the outcomes in people with RMDs.
Read ArticleBurnout Threatens the Rheumatology Workforce Conundrum
There is a shortage of rheumatologists in Canada and the recent 2020 Canadian Rheumatology Association (CRA) Workforce and Wellness study shows that the shortage may be compounded by rheumatologist burnout, especially among young and female physicians.
Read ArticleCC Genotype and Thiopurine Toxicity
Annals of Internal Medicine reports that thiopurine toxcicity risk is associated with the "CC" genotype and that azathioprine discontinuation was associated with hematopoietic toxicity and lower thiopurine doses.
Read ArticleWhat Happened to Kawasaki Disease During COVID-19?
During the COVID-19 pandemic, a new COVID-related syndrome in children, the "Multisystem inflammatory syndrome in children" (MIS), was described as being similar to but distinctly different than childhood Kawasaki's disease (KD). A new epidemiologic report shows that while MIS-C cases rose, KD cases fell and remained low during the period of masking and school closure.
Read ArticleTwo Week Twitter (6.17.2022)
Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.
Read ArticleFlares Not Increased Following Recombinant Zoster Vaccine Injections
Insurance claims analysis has shown that the use of the (CDC recommended) recombinant zoster vaccine (RZV) for prevention of herpes zoster was highly used in patients with immune-mediated inflammatory diseases and was safe, as higher rates of arthritis flares were not evident.
Read ArticleImproved Pregnancy Outcomes in SLE (2010–2020)
A retrospective cohort study has shown that outcomes in pregnant systemic lupus erythematosus (SLE) patients has significantly improved in the last decade, but there still is a high risk of adverse pregnancy outcomes (APO).
Read ArticleACR Applauds FTC Decision to Investigate PBM's
The American College of Rheumatology applauds the Federal Trade Commission’s decision to investigate the business practices of pharmacy benefit managers (PBMs), which continue to increase PBM profit margins while placing the burden of skyrocketing drug costs on America’s most vulnerable patients,
Read ArticleWhat do our lupus patients think about treat-to-target?
In SLE, two targets that are increasingly used are the DORIS 2021 Remission and the Lupus Low Disease Activity (LLDAS). T2T is more likely to be successful if the treating clinicians and the patients set the treatment goals together. What do our patients think about T2T and do they have any say/concern?
Read ArticleMMWR: Monkeypox Outbreak in Nine States
CDC is tracking multiple reported U.S. monkeypox cases, and monitoring cases in persons in countries without endemic monkeypox and with no known travel links to an endemic area; current epidemiology suggests person-to-person community spread.
Read ArticleGout Undertreatment Persists
Despite updated gout management guidelines from European (EULAR) and British (BSR) societies, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.
Read ArticleBSR Guideline for Psoriatic Arthritis - 2022 Update
The British Society of Rheumatology has published their updated 2022 recommendations for the use of biologics and targeted synthetic treatments in patients with psoriatic arthritis. These guidelines follow initial treatment with a single conventional systemic disease-modifying anti-rheumatic drug, typically methotrexate typically. They noted that up to 50% of people with PsA require biologic or targeted synthetic (b/ts)DMARD therapy.
Read ArticleEULAR 2022 – Day 4 Report
Bags are packed, ready to go, but wait there’s more abstracts to show.
The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased.
Read ArticleEULAR 2022 – Day 3 Report
By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
Read Article


